ClinicalTrials.gg
TerminatedNCT05709093Updated Apr 27, 2025

A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

A Phase 3 interventional study of Lemzoparlimab+Azacitidine (AZA) and Azacitidine (AZA) in Myelodysplastic Syndromes(MDS), sponsored by TJ Biopharma Co., Ltd.. Terminated at 44 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by TJ Biopharma Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Company Development strategy adjustment\]

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.

Enrollment
106th of 126
10 · median 38
Started
2023
with 3 others
Phase 3
9 of 130
1 open now
Registered
116th of 130
by date

Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 106th largest by enrollment of the 126 interventional ones that give a count, is one of 4 that started in 2023, is one of 9 in phase 3, and was the 116th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 318 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 259 Myelodysplastic Syndromes studies recruiting now, 166 (64%) set no upper age limit and 67 (26%) stop at 75 or younger; 55 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing azacitidine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

This phase3 study is a randomized, controlled, open-label, multicenter study to evaluate the efficacy and safety of Lemzoparlimab for injection in combination with AZA versus AZA monotherapy as first-line therapy in treatment-naïve subjects with intermediate- and high-risk MDS.

03

Conditions studied

  • Myelodysplastic Syndromes(MDS)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, ≥ 18 years of age at the time of signing the ICF.
  • Subjects with intermediate- and high-risk MDS who are confirmed by bone marrow aspiration or pathological according to the diagnostic criteria of World Health Organization (WHO) 2016 or who are eligible for blasts in bone marrow and peripheral blood \< 20% and have a score > 3.5 according to the revised International Prognostic Scoring System (IPSS-R).
  • (ECOG) performance status score of 0 to 2.
  • Subjects without any prior anti-tumor therapy for MDS, including demethylated drugs (eg, AZA, decitabine), chemotherapy, targeted therapy, or . The blood transfusion or use of hematopoietic growth factors and supplementation of hematopoietic raw materials such as folic acid, vitamin B12 are permitted. For patients who ever took lenalidomide, thalidomide, antithymocyte globulin (ATG), or ciclosporin before study entry, there should be a of at least 28 days prior to the first dose.
  • Subjects who are eligible for HSCT and have no pre-scheduled HSCT at screening, or subjects who are ineligible for HSCT and have no scheduled HSCT at screening
  • Expected survival ≥ 12 weeks
  • Subjects with adequate organ function and laboratory tests meet the following requirements
  • Female subjects of or male subjects whose partner is a woman of childbearing potential are required to use effective throughout the treatment period and until 6 months after the treatment period.
  • Subjects must be willing to provide available diagnostic evidence or undergo bone marrow aspiration and biopsy before study treatment, and must be willing to undergo bone marrow aspiration and biopsy after receiving study treatment.
  • Subjects must give before starting the study and sign written ICF voluntarily by themselves (or their legal representatives). Subjects or their legal representatives should be able to communicate well with investigators and agree to adhere with the study protocol and complete the study

Exclusion criteria

Exclusion Criteria:

  • Patients who have transformed from MDS to AML, or have been diagnosed with treatment-related MDS (t-MDS), or patients with myeloproliferative neoplasia (MPN) or myelodysplastic syndrome/myeloproliferative disorder (MDS/MPN) that meet WHO 2016 criteria
  • Previously received any anti-7 antibody or SIRPα antibody or the drugs targeting the same target
  • Subjects have received or plan to receive the stem cell transplantation or organ transplantation during the study
  • History of chronic hemolytic anemia due to other diseases or positive hemolysis-related test at screening (except positive hemolysis test due to MDS)
  • Concurrent participation in another interventional clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
  • Subjects plan to receive other anti-tumor therapies, including but not limited to chemotherapy, biotherapy and immunotherapy, while participating in the study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Lemzoparlimab in combination with AZA

    Drug: Lemzoparlimab+Azacitidine (AZA)

  • Active comparator
    AZA monotherapy

    Drug: Azacitidine (AZA)

Interventions

  • DrugLemzoparlimab+Azacitidine (AZA)

    Drug pages: LemzoparlimabStudies of LemzoparlimabLemzoparlimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AzacitidineStudies of AzacitidineAzacitidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1. Lemzoparlimab is administered by intravenous (IV) infusion once a week at a dose of 30 mg/kg in 28-day treatment cycles 2. Azacitidine (AZA): AZA is administered by subcutaneous injection once a day at a dose of 75 mg/m2 on D1 to D7 of each treatment cycle in 28-day treatment cycles.

  • DrugAzacitidineStudies of AzacitidineAzacitidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    AZA is administered by subcutaneous injection once a day at a dose of 75 mg/m2 on D1 to D7 of each treatment cycle in 28-day treatment cycles.

06

What researchers measure

Primary outcomes

  1. Overall Survival Overall Survival(OS)

    Time frame: From date of randomization until the date of first documented progression or date from any cause,whichever came first, assessed up to 50 months.

07

Study locations

44 sites
  • The First Affiliated Hospital Of Bengbu Medical College
    Bengbu, An Hui 233099, China
  • THE First Affiliated Hospital Of Anhui Medical University
    Hefei, An Hui 230022, China
  • The First Affilated Hospital Of USTC Anhui Provincial Hospital
    Hefei, Anhui 230001, China
  • Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, Bei Jing 100037, China
  • Beijing Gaobo Boren Hospital Co., Ltd
    Beijing, Bei Jing 100070, China
  • Peking University Third Hospital
    Beijing, Bei Jing 100191, China
  • The First Affiliated Hospital of PLA Army Military Medical University
    Chongqing, Chong Qing 400037, China
  • The Second Affiliated Hospital of Army Medical University
    Chongqing, Chong Qing 400037, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chong Qing 400042, China
  • The Affiliated Zhongshan Hospital of Xiamen University
    Xiamen, Fu Jian 61004, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guang Dong 510120, China
  • Zhujiang Hospital of Southern Medical University
    Guangzhou, Guang Dong 510260, China
  • Southern Hospital of Southern Medical University
    Guangzhou, Guang Dong 516006, China
  • Guangdong Provincial People's Hospital
    Guangzhou, Guang Dong 519041, China
  • Shenzhen Second People's Hospital
    Shenzhen, Guang Dong 518025, China
  • First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, He Nan 450052, China
  • Henan Cancer Hospital
    Zhengzhou, He Nan 450003, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, He Nan 450052, China
  • Henan Provincial People's Hospital
    Zhengzhou, He Nan 463599, China
  • Harbin First Hospital
    Harbin, Hei Long Jiang 150010, China
  • Tongji Medical College of HUST
    Wuhan, Hu Bei 30030, China
  • Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Changsha Third Hospital
    Changsha, Hunan 410035, China
  • The first hospital of Jilin University
    Chang chun, Ji Lin 130061, China
  • The Affiliated Hosptial Of XuZhou Medical University
    Xuzhou, Jiang Su 221004, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiang XI 330006, China
  • The First Affiliated Hospital of China Medical University
    Shenyang, Liaoning 110002, China
  • Shaanxi Provincial People's Hospital
    Xian, Shaan XI 710068, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University Medical College
    Xi'an, Shaanxi 710004, China
  • Cheeloo College of Medicine, Shandong University
    Jinan, Shan Dong 250063, China
  • The Affiliated Hospital of Medical College Qingdao University
    Qingdao, Shan Dong 266003, China
  • The Second Affiliated Hospital of Shandong First Medical University
    Tai'an, Shan Dong 271099, China
  • Taian City Central Hospital
    Taian, Shan Dong 271099, China
  • Shanxi Bethune Hospital
    Taiyuan, Shan XI 30032, China
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shang Hai 200025, China
  • Tongji Hospital of Tongji University
    Shanghai, Shang Hai 200065, China
  • Renji Hospital Affiliated to Medical College of Shanghai Jiaotong University
    Shanghai, Shang Hai 200120, China
  • Shanghai Sixth People's Hospital
    Shanghai, Shanghai 201306, China
  • West China Hospital of Sichuan University
    Chengdu, Si Chuan 610044, China
  • Affiliated Hospital of North Sichuan Medical College
    Nanchong, Si Chuan 637000, China
  • Tianjin Medical University General Hospital
    Tianjin, Tian Jin 300052, China
  • Hematology Hospital of Chinese Academy of Medical Sciences
    Tianjin, Tianjin 300020, China
  • The First Affiliated Hospital of Zhejiang University Medical College
    Hangzhou, Zhe Jiang 310003, China
  • The First Affiliated Hospital Of WenZhou Medical College
    Wenzhou, Zhejiang 325015, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Apr 2024, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2023
First posted
Feb 1, 2023
StartActual
Mar 30, 2023
Primary completionActual
Apr 1, 2024
CompletionActual
Apr 1, 2024
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05709093
Lead sponsor
TJ Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
Feb 1, 2023
Start date
Mar 30, 2023
Primary completion
Apr 1, 2024
Completion
Apr 1, 2024
Last update
Apr 27, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lemzoparlimab · Azacitidine

Start the discussion